One paper presented at IEEE International Conference on Future Machine Learning and Data Science 2025 covers Verseon's superior predictions of…
Launched in 2019, the Syn-One Test is used by neurologists and other clinicians in all 50 states to aid in…
ZURICH, Nov. 6, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for…
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate…
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate…
Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of…
Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of…
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer…
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer…
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trialsIntroduces first trispecific molecules, APVO451…